Combretum quadrangulare

Combretum quadrangulare contains a diverse array of flavonoids—including ayanin, rhamnocitrin, ombuin, kumatakenin, luteolin, apigenin, and vitexin—alongside a hepatoprotective gallic acid glycoside, which collectively inhibit alpha-glucosidase (IC₅₀ 30.5–282.0 µM), HIV-1 integrase (IC₅₀ 2.5–2.9 µg/mL in root/seed extracts), and protect hepatocytes from TNF-α-induced cell death. Preclinical data show antiplasmodial activity against Plasmodium falciparum K1 with IC₅₀ values as low as 1.25 µg/mL in methanolic stem extracts, and moderate antibacterial activity against MRSA, though no human clinical trials have yet confirmed these effects in vivo.

Origin & History

Combretum quadrangulare Kurz is native to mainland Southeast Asia, with documented distribution across Thailand, Vietnam, Myanmar, and Cambodia, where it grows in tropical and subtropical lowland forests and disturbed secondary vegetation. The plant belongs to the Combretaceae family and thrives in humid, warm climates with seasonal rainfall typical of the Indochinese peninsula. Leaves, roots, seeds, and stem bark are all harvested from wild populations for traditional medicinal use, with no large-scale commercial cultivation currently documented.

Historical & Cultural Context

Combretum quadrangulare has been employed in traditional medicine across Thailand and Vietnam for centuries, with documented uses encompassing wound treatment, management of diarrheal illness, hepatic complaints, parasitic infections, and febrile conditions consistent with malaria-endemic environments. In Thai ethnobotany, the plant is used topically and internally, with leaf preparations applied to wounds and decoctions consumed for gastrointestinal disorders, reflecting the convergent discovery of its antimicrobial and anti-inflammatory properties across regional healing traditions. Vietnamese traditional practitioners similarly employ the plant for infections and liver conditions, and phytochemical investigation of Vietnamese specimens has identified a distinct but overlapping flavonoid profile compared to Thai collections, suggesting some regional chemotypic variation. Pharmacognostic interest in the genus Combretum dates to the 1970s when secondary metabolite isolation began systematically documenting the flavonoid richness of the Combretaceae family, and C. quadrangulare has been a subject of increasing phytochemical scrutiny since that period.

Health Benefits

- **Antiplasmodial Activity**: Ethanolic leaf, root, and stem bark extracts demonstrate inhibitory activity against chloroquine-resistant Plasmodium falciparum K1 strain, with methanolic stem extracts achieving IC₅₀ values of 1.25 µg/mL, suggesting potential utility as an adjunct antimalarial botanical pending clinical validation.
- **Alpha-Glucosidase Inhibition (Antidiabetic Potential)**: Flavonoids including ayanin, rhamnocitrin, ombuin, and synthetic brominated analogues inhibit alpha-glucosidase with IC₅₀ values ranging 30.5–282.0 µM; brominated derivatives act via noncompetitive inhibition, binding allosteric sites outside the enzyme active site, which may slow postprandial glucose absorption.
- **Hepatoprotection**: A purified O-galloyl-6-O-(4-hydroxy-3,5-dimethoxy)benzoyl-β-D-glucose derivative from methanolic extracts protects hepatocytes against D-galactosamine/TNF-α-induced apoptosis, and the crude methanolic extract reduced serum glutamate pyruvate transaminase (GPT) in LPS-challenged mice (extract IC₅₀ 56.4 µg/mL).
- **Antiviral (HIV-1 Integrase Inhibition)**: Aqueous and ethanolic root and seed extracts inhibit HIV-1 integrase with IC₅₀ values of 2.5–2.9 µg/mL in cell-free enzymatic assays, suggesting flavonoid and polyphenolic constituents may interfere with strand-transfer steps of viral DNA integration.
- **Antibacterial Activity**: Isolated flavonoids rhamnocitrin and ombuin exhibit moderate antibacterial action against methicillin-resistant Staphylococcus aureus (MRSA), with activity attributed to flavonoid-mediated disruption of bacterial membrane integrity and inhibition of bacterial target enzymes, though they were inactive against ESBL-producing Escherichia coli.
- **Anthelmintic Properties**: Ether and ethanolic root and seed extracts produced in vitro killing of earthworms (Pheretima posthuma), consistent with the broad genus-level anthelmintic tradition; this activity is analogous to findings in the related species Combretum mucronatum, which showed activity in a human guinea worm trial at 0.03 mg/kg.
- **Antioxidant and Anti-inflammatory Effects**: The rich flavonoid and tannin content—including myricetin derivatives, quercetin-3,4-dimethyl ether, and gallic acid conjugates—confer free radical scavenging and anti-inflammatory properties that underpin the plant's traditional use for wound healing and diarrhea management in Thai and Vietnamese ethnomedicine.

How It Works

The primary mechanism of antidiabetic activity involves competitive and noncompetitive inhibition of intestinal alpha-glucosidase by flavonoids such as ayanin, rhamnocitrin, and ombuin, with brominated synthetic analogues (compounds 8 and 11) confirmed via enzyme kinetics and molecular docking to occupy allosteric binding sites distinct from the catalytic active site, thereby reducing the rate of oligosaccharide hydrolysis and postprandial glucose release. Hepatoprotection is mediated by the gallic acid glycoside O-galloyl-6-O-(4-hydroxy-3,5-dimethoxy)benzoyl-β-D-glucose, which suppresses TNF-α-triggered hepatocyte apoptosis through antioxidant scavenging and likely NF-κB pathway modulation, reducing oxidative stress markers including serum GPT in murine LPS models. HIV-1 integrase inhibition by root and seed extracts (aqueous IC₅₀ 2.5 µg/mL; ethanolic IC₅₀ 2.9 µg/mL) is attributed to polyphenolic constituents that chelate the Mg²⁺ cofactor in the integrase active site or sterically obstruct the strand-transfer reaction, though specific residue-level interactions have not been fully characterized. Antibacterial activity against MRSA by rhamnocitrin and ombuin likely reflects flavonoid-mediated inhibition of bacterial DNA gyrase or disruption of cytoplasmic membrane potential, consistent with class-wide mechanisms established for structurally related flavones.

Scientific Research

The evidence base for Combretum quadrangulare consists entirely of in vitro biochemical assays, phytochemical isolation studies, and a small number of rodent in vivo experiments, with zero published human clinical trials specifically on this species as of the available literature. Antiplasmodial activity has been assessed against P. falciparum K1 in multiple extract screenings (IC₅₀ 1.25–4.0 µg/mL), and the hepatoprotective gallic acid derivative was evaluated in D-galactosamine/LPS-challenged mice, though sample sizes and full statistical reporting are absent from available sources. Alpha-glucosidase inhibition data are the most mechanistically detailed, supported by enzyme kinetics experiments and in silico molecular docking for brominated flavonoid analogues, lending moderate confidence to this specific pharmacological claim within preclinical parameters. A single human trial exists within the Combretum genus (C. mucronatum in 88 adults with guinea worm infection), providing indirect contextual support for anthelmintic activity, but this cannot be extrapolated directly to C. quadrangulare without species-specific clinical study.

Clinical Summary

No randomized controlled trials, observational cohort studies, or other formal clinical investigations have been conducted specifically with Combretum quadrangulare in human participants, representing a significant gap in the evidence base. The only genus-level human data derive from a single trial of Combretum mucronatum (n=88) for guinea worm infection at 0.03 mg/kg orally, which reported activity but lacked detailed effect sizes and statistical methodology in the available summary. Preclinical outcomes in rodents—including serum GPT reduction in LPS/D-GalN hepatotoxicity models and earthworm killing in anthelmintic assays—provide hypothesis-generating data but cannot establish clinical efficacy or safe dosing ranges for humans. Confidence in therapeutic benefit for any indication remains very low, and all traditional medicinal uses require prospective clinical validation before evidence-based recommendations can be made.

Nutritional Profile

Combretum quadrangulare is a medicinal botanical rather than a dietary food, and no conventional macronutrient or micronutrient profile has been established through proximate analysis. The dominant phytochemical constituents are polymethoxylated and hydroxylated flavonoids—including kumatakenin, ayanin, rhamnocitrin, ombuin, luteolin, apigenin, vitexin, isoorientin, mearnsetin, gardenin D, quercetin-3,4-dimethyl ether, combretol, myricetin-3,3,4-trimethyl ether, and myricetin-3,7,3',5'-tetramethyl ether—alongside hydrolyzable tannins and the gallic acid glycoside O-galloyl-6-O-(4-hydroxy-3,5-dimethoxy)benzoyl-β-D-glucose. Quantitative concentrations (mg/g dry weight) for individual phytochemicals have not been reported in available studies; yields vary significantly by plant part (leaves yield flavonoids most abundantly), extraction solvent polarity (ether vs. MeOH vs. water), and geographic provenance. Bioavailability of these flavonoids in humans is entirely unstudied for this species, though polymethoxylated flavones as a class are generally better absorbed than their polyhydroxylated counterparts due to reduced first-pass glucuronidation.

Preparation & Dosage

- **Traditional Leaf Decoction (Thai/Vietnamese medicine)**: Dried leaves are boiled in water or extracted with 90–95% ethanol for wound-washing preparations and antidiarrheal decoctions; no standardized dose is established.
- **Methanolic/Ethanolic Extract (Preclinical research)**: Root, seed, and stem bark extracted with MeOH or 90–95% EtOH; in vitro antiplasmodial activity observed at 1.25–4.0 µg/mL, with hepatoprotective extract activity at IC₅₀ 56.4 µg/mL; these are in vitro concentrations and do not translate directly to oral dosing.
- **Aqueous Extract (Antiviral research)**: Water-extracted root and seed material inhibited HIV-1 integrase at IC₅₀ 2.5 µg/mL in enzymatic assay; no oral bioavailability data are available to inform human dosing.
- **Ether/Dichloromethane Extract (Anthelmintic use)**: Ether and methylene chloride extracts of roots and seeds demonstrated in vitro anthelmintic activity; preparation involves cold maceration or Soxhlet extraction of dried root material.
- **No Commercial Supplement Form Established**: Combretum quadrangulare is not currently available as a standardized capsule, tablet, or tincture with defined phytochemical specifications; no standardization percentages for flavonoid content have been validated for commercial use.
- **Timing**: No clinical timing data exist; traditional preparations are typically administered acutely for infection or wound management rather than as chronic supplementation.

Synergy & Pairings

Within the flavonoid pharmacology literature, quercetin and luteolin—both identified in C. quadrangulare—are known to synergize with gallic acid derivatives through complementary free radical scavenging pathways (hydrogen atom transfer vs. single electron transfer), suggesting the plant's mixed flavonoid-tannin profile may produce additive antioxidant effects greater than individual isolates alone. For antiplasmodial applications, co-administration of plant-derived flavonoids with artemisinin-based compounds has shown synergistic activity in related Combretum genus research, though no specific combination studies have been performed with C. quadrangulare extracts. The alpha-glucosidase inhibitory flavonoids (ayanin, rhamnocitrin) may theoretically potentiate dietary fiber-based glucose management strategies by acting through a complementary intestinal carbohydrate hydrolysis pathway, representing a logical stack for glycemic support formulations pending clinical investigation.

Safety & Interactions

No adverse effects, toxicity signals, or safety concerns have been formally documented in the available preclinical literature on Combretum quadrangulare; in vitro studies note that cytotoxic effects appear limited to targeted biological activities rather than nonspecific cellular toxicity, though systematic toxicological evaluation (LD₅₀, subchronic toxicity, genotoxicity) has not been published. Drug interactions have not been studied; however, the demonstrated alpha-glucosidase inhibitory activity of constituent flavonoids raises theoretical concern for additive hypoglycemic effects when combined with antidiabetic medications such as acarbose, metformin, or sulfonylureas, requiring monitoring if co-administered. The HIV-1 integrase inhibitory activity of extracts is a theoretical interaction concern with antiretroviral drugs (specifically integrase strand transfer inhibitors such as raltegravir or dolutegravir), though no pharmacokinetic or pharmacodynamic data exist to quantify this risk. Pregnancy and lactation safety are entirely uncharacterized; in the absence of any human safety data, use during pregnancy, lactation, or in pediatric populations cannot be recommended, and the maximum safe dose for any indication remains undefined.